Tag Archives: Johnson & Johnson

Progress Report: New Antibacterials In the Fight against MDR Bacteria

Posted on by — No Comments ↓

Since the beginning of this millennium we have seen antibiotic R&D dwindle year after year. There are many reasons for this; while economics are often cited for this decline, the FDA and the ‘Guideline Wars’, i.e., those never ending discussions about regulatory requirements, have contributed to this trend in a Continue reading Progress Report: New Antibacterials In the Fight against MDR Bacteria→

There is Momentum Building for RSV Therapeutics

Posted on by — No Comments ↓

Sometimes – for no obvious reason – there is a flurry of publications from a particular area which has been quiet for a long time.  RSV is such an area where new drug development had a hard time getting started.  There was always the lure of big money: an infection Continue reading There is Momentum Building for RSV Therapeutics→

The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?

Posted on by — No Comments ↓

Any FDA meeting is a high-stakes game for industry:  One never knows how the discussions will go. Some oddball issue may take center stage and usurp much time, creating an unbalanced perspective.  At other times, simple issues seem to create controversy, questions are not properly understood in the context of Continue reading The FDA AMDAC on Fluoroquinolones (Part 2): Where Were the FQ Advocates?→